Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) has announced that CEO Dr Roger McIntyre has been elected chairman of its board of directors.
A foremost international expert in depression and suicide, Dr McIntyre is a professor of psychiatry and pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto, and has appointments among scientific and clinical organizations across the US and Asia, the company said in a statement Monday
Dr McIntyre was appointed to the board on July 22 after assuming the role of CEO in May.
READ: Champignon Brands to offer esketamine for depression at Ontario clinic
Champignon Brands said the CEO has set out a strategic direction for the business which includes a focus on "breakthrough treatments of depression" through the development of government-approved ketamine compounds and a network of treatment clinics.
The company's dual mission is to help those suffering from mental health disorders in its own ketamine-based clinics and to develop the next generation of novel psychedelic treatments and delivery systems.
Champignon Brands said it continues to work with the British Columbia Securities Commission to address the ongoing continuous disclosure review and is confident that the review will be resolved soon.
In other company news, Bill Wilkerson, who was appointed to the board in May, has been elected vice-chair, bringing to the position extensive experience in business, government, and mental health.
Champignon, based in Vancouver, specializes in the formulation of a suite of medicinal mushrooms health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness, and alternative medicine industries.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham